INTRODUCTION
============

Despite numerous antihypertensive agents, hypertension is still not adequately controlled \[[@R1]-[@R3]\]. This can be attributed to a combination of psychosocial, socio-economic, environmental and physician-related effects, but also to a genetic predisposition. The genetic influence of blood pressure (BP) variation is expected to be approximately 30-40% \[[@R4],[@R5]\]. Until now, more than 150 candidate genes have been associated with BP regulation. In this context, genes such as angiotensinogen (*AGT*) and angiotensin-1-converting enzyme (*ACE*), which encode proteins of the renin-angiotensin system (RAS) have been widely evaluated \[[@R6],[@R7]\].

AGT is the natural substrate of RAS produced in the liver. The associations of these variants are contradictory in different populations \[[@R8]\]. The *AGT* gene is located at lq42-43 and consists of 5 exons and 4 introns spanning 13 kb \[[@R9]\]. The *AGT* gene is a logical candidate for BP control, taking into consideration the strong correlation between plasma AGT levels and BP \[[@R10]\]. Although several polymorphisms in the *AGT* region have been recognized \[[@R11]\], a special focus has been focused on 2 polymorphisms, *M235T (rs699*) and *T174M (rs4762*), both found in exon 2.

ACE is a key zinc metallo-enzyme of the RAS widely allocated in the kidney \[[@R12]\]. ACE catalyzes the conversion of angiotensin I to the biologically active peptide, angiotensin II, which is involved in the control of fluid electrolyte balance and systemic BP \[[@R12]\]. This poly-morphism is characterized by the presence (insertion) or absence (deletion) of a 287 bp AluYa5 element inside intron 16. *ACEI/D* gene polymorphism has been associated with the presence of essential hypertension \[[@R13],[@R14]\].

Several antihypertensive drugs target RAS pathways such as ramipril, an ACE inhibitor, involved in the treatment of hypertension and congestive heart failure. In the present study, we evaluated the frequency of 3 Simple Nucleotide Polymorphisms (SNPs) such as *AGTM235T (rs699), AGTT174M (rs4762)*and*ACEI/D (rs1799752)* in hypertensive and normotensive individuals as well as the possible influence of these Single Nucleotide Polymor-phisms (SNPs) on ramipril-induced BP lowering.

PATIENTS AND METHODOLOGY
========================

The present study was designed and performed in agreement with the recommendations for the human genotype-phenotype association studies published by the NCI-NHGRI (National Cancer Institute-National Human Genome Research Institute) Working Group on Replication in Association Studies \[[@R15]\] indicated time period and location of subject recruitment, success rate for DNA acquisition, internal control samples (from the same DNA) and sample tracking methods.

*Subjects:*A total of 166 participants were included in the present study divided into 2 groups. Control group (n = 83, 56 ± 20 years, 44 men): subjects were recruited from the outpatient clinics of the Orthopedic and Urologic Departments of the Veterans Administration Hospital (NIMTS). Inclusion criteria were: age 18 -\<80 years, no history of coronary artery disease, diabetes mellitus, thyroid and liver disease, heart and renal failure, high alcohol consumption, professional athleticism and any chronic disease, hypertension or antihypertensive drug therapy and BP within normal limits according to current guidelines \[[@R16],[@R17]\].

Hypertensive group (n = 83, 67 ± 13 years, 48 men): newly-diagnosed hypertensive patients were randomly recruited from the Outpatient Clinic of the Onassis Cardiac Surgery Centre. Inclusion criteria were age 18 - \< 80 years, no history of thyroid and liver disease, heart and renal failure, high alcohol consumption, and elevated BP (hypertension was defined as systolic BP \>140 mmHg and/or diastolic BP \>90 mmHg). These patients had no prior or current use of antihypertensive agents. BP was measured twice and the lower value was recorded. The measurement was performed on the right upper arm by auscultation method after the subject had been seated for at least 5 min. Mercury sphygmomanometers were used and the appropriate adult cuff size was applied. Secondary hypertension was excluded by the use of a detailed health questionnaire.

Written consent was obtained from each participant. The study protocol was approved by the institutional ethics committee (Onassis Cardiac Surgery Center, Athens, Greece) and was in accordance with the Declaration of Helsinki for Human Research of 1974 (last modified in 2000). All study cohorts were of Caucasian origin and descent for ≥3 generations.

RAMIPRIL ADMINISTRATION
=======================

We initially administered ramipril monotherapy in the hypertensive patients (dose ranged from 2.5 to 10 mg daily, according to BP values), followed by combination therapy (i.e. addition of a diuretic) if needed. The associations between genotypes of the 3 candidate genes and BP decrease by ramipril monotherapy were evaluated.

GENOTYPING
==========

Genotyping was performed for research purposes. Extraction of genomic DNA was performed from leukocytes separated from whole blood using a standard method with Qiagen FlexiGene DNA kit.

The oligonucleotide primers used for AGTM235T (rs699) polymorphism were 5'-CCGTTTGTGCAGGGCCT GGCTCTC -3' and 5'-CAGGGTGTCCACACTGGCTCG −3 as described by Bennett *et al.* \[[@R18]\]. Polymerase Chain Reaction (PCR) was subjected to 95 ^ο^C for 5 min, 30 cycles of 95^ο^C for 30 s, 55^ο^C for 30 s and 72^ο^C for 30 s and final extension to 72^ο^C for 7 min, producing a fragment of 165 bp. This fragment was subsequently cleaved by restriction enzyme BstUI (Bacillus stearothermophilus U458), creating fragments for T allele 141 bp and 24 bp and for M allele 165 bp, which were subjected to electrophoresis on an agarose gel 4% and visualized with ethidium bromide (Fig. **[1](#F1){ref-type="fig"}**).

The oligonucleotide primers used for *AGTT174M (rs4762)* polymorphism were 5'-CAGGGCTGATAGCCAG GCCCA-3' and 5'-GAGAGCCAGGCCCTGCACAAA−3. PCR was subjected to 95 ^ο^C for 5 min, thirty five cycles of 95^ο^C for 30 s, 64^ο^C for 30 s and 72^ο^C for 30 s and final extension to 72^ο^C for 7 min, producing a fragment of 103 bp. This fragment was subsequently cleaved by restriction enzyme NcoI (Nocardia coralline), creating fragments for M allele 70 bp and 33 bp and for T allele 103 bp, which were subjected to electrophoresis on an agarose gel 4% and visualized with ethidium bromide (Fig. **[2](#F2){ref-type="fig"}**).

The polymorphism *ACEI/D*(rs1799752) within the *ACE* gene was analyzed as previously described \[[@R6]\]. The PCR product is a fragment of 190 bp when the insertion is absent and 490 bp when the insertion is present analyzed by electrophoresis on a 4% agarose gel stained with ethidium bromide.

STATISTICAL ANALYSIS
====================

All continuous variables are presented as mean ± standard deviation while the categorical ones as absolute (N) and relative (percentage) frequencies. Independent samples t-test was used to investigate for any differences of the continuous variables between the two study groups, while paired samples t-test was used in order to evaluate the differences in BP variables between baseline and after treatment. Pearson's chi-square or Fisher's exact statistic were used for testing of potential associations between categorical variables. Univariate logistic regression models were constructed in order to quantify any significant association that could derive from the simple associations. All tests were two-sided at a significance level of p\<0.05. Data were analyzed using STATA™ (Version 13.0, Stata Corporation, College Station, TX 77845, USA).

RESULTS
=======

There were no failures in sample collection, DNA acquisition or genotyping procedures.

CLINICAL AND LABORATORY PARAMETERS
==================================

Demographic data, clinical characteristics and lipid profile of the study groups are shown in Table **[1](#T1){ref-type="table"}**. By definition of the study protocol the prevalence of coronary artery disease, stroke and diabetes mellitus was presented in the hypertensive group only (28.9, 4.8 and 27.7%, respectively). Furthermore 12% were current smokers compared with the Control group where smokers were nearly 3 times higher, p=0.001. Age, body mass index (BMI), total cholesterol (TC), triglycerides (TGs) and low-density lipoprotein cholesterol (LDL-C) were significantly lower in the Control group compared with the hypertensive group (p=0.01 for all comparisons).

GENE FREQUENCY AND HYPERTENSION
===============================

Genotype frequencies are shown in Table **[2](#T2){ref-type="table"}**. The genotype and allele distribution of the *AGTM235T* variant significantly differed between hypertensives and normotensives odds ratio (OR) = 1.57% (*T* vs *M* allele), 95% confidence intervals (CIs): 1.01 - 2.44; p = 0.045 for hypertensives in the ramipril group\]. Specifically, the hypertensive group had more frequently the *TT* genotype compared with normotensive controls, p=0.042, Table 2. However, neither the aforementioned association nor any other cross-tabulation between genotype and allele distribution and study group were significant when tested by gender.

GENE POLYMORPHISMS AND RAMIPRIL TREATMENT
=========================================

None of the 3 studied SNPs were associated with the BP-lowering response to ramipril (Tables**3-5**). Genotype and allele frequencies of *AGTM235T*, *AGTT174M* and *ACEI/D* gene polymorphisms were evaluated according to BP-lowering response define as Grade 1 hypertension (140-159 and/or 90-99 mmHg), High normal (130-139 and/or 85-89 mmHg), Normal (120-129 and/or 80-84 mmHg) and Optimal (\<120/\<80 mmHg).

DISCUSSION
==========

As there is a genetic predisposition to hypertension and elevated BP is inadequately controlled, several candidate genes have been investigated with regard to BP regulation. *AGT* and *ACE* genes that affect the RAS have been widely evaluated \[[@R6],[@R7]\]. In the present study, we evaluated 3 SNPs in 2 candidate genes involved in RAS-related pathways, also investigating their potential impact on ramipril monotherapy efficacy. We found that *AGTM253T (rs699*) gene polymorphism frequency is different between hypertensives and controls. No differences in the frequency of *AGTT174M (rs4762)* and *ACEI/D (rs1799752)* gene polymorphisms between the 2 study groups were observed. Furthermore, none of these 3 SNPs was shown to affect the BP-lowering effects of ramipril monotherapy.

Jeunemaitre *et al.* \[[@R9]\] originally explored the potential role of *AGT* gene in hypertension through a linkage study. Two different meta-analyses in Chinese populations confirmed that the *T* allele of *AGTM235T* polymorphism is associated with essential hypertension \[[@R19],[@R20]\]. However, Niu et al found no association of essential hypertension with *AGTM235T* or*AGTT174M*polymorphisms, even after stratification by age, gender or disease severity \[[@R21]\]. Similarly, Caulfield *et al.* \[[@R22]\] did not report any association with either *AGTM235T*or *AGTT174M* gene polymorphisms. Mohana *et al.*\[[@R23]\] reported an increase in the risk for hypertension in women only with the *AGTM235T* polymorphism (OR = 2.82; 95% CI = 1.22-6.49; p=0.012). Therefore, some studies confirm the association \[[@R11],[@R24]\] and others refute it \[[@R25]-[@R27]\]. In our study, the hypertensive group had approximately 3 times more frequently the *TT* genotype of the *AGTM235T* gene polymorphism compared with normotensive controls, p=0.042.

With regard to the *AGTT174M*polymorphism, Mohana *et al.* \[[@R23]\] reported significant differences between hypertensives and normotensives. Also, a meta-analysis of the association of 4 *AGT*polymorphisms with essential hypertension confirmed this association \[[@R28]\]. Although an analysis by ancestry revealed that in Asian and mixed populations the *174M*allele was associated with an increased risk for hypertension (OR: 1.31; 95% CI: 1.02 - 1.69; p = 0.04 and OR: 1.43; 95% CI: 1.11 - 1.83; p = 0.005, respectively), no clear evidence for a role of this variant is observed in European ethnicity populations (OR: 1.03; 95% CI: 0.92 - 1.15; p = 0.61) \[[@R25]\]. In our study, we did not find any differences in the frequency of this polymorphism between the 2 study groups.

With regard to *ACEI/D* gene polymorphisms, there are studies with inconsistent results. Dhanachandra Singh Kh *et al.* \[[@R29]\] found overrepresentation of the *ACE I* allele in normotensive males, thus suggesting its protective role. He *et al.* \[[@R13]\] also found that the *ACEI/D* gene polymorphism plays a role in hypertension. Furthermore, meta-analyses reported that *DD* genotype of the *ACEI/D* polymorphism \[[@R14]\] were associated with essential hypertension. In the present study, we did not observe any differences in *ACEI/D* gene polymorphism frequency between the 2 study groups. Similarly, no association was found in Chinese, Italian, Greek, Japan and Indian populations \[[@R30],[@R31]\]. Whether this disagreement is due to racial, environmental factors or the inclusion criteria used in each study is unknown and needs additional investigation.

There are only a few studies evaluating the association between *AGTM235T, AGTT174M*and*ACEI/D*gene polymorphisms with the BP-lowering effect of ramipril. Zivko *et al.* \[[@R32]\] did not find any significant impact of *ACEI/D* gene polymorphisms on ramipril-related BP-decreasing effect in 66 hypertensive patients. Similarly, in the present study, we did not observe any significant differences in BP changes with regard to *I/D* polymorphism. In contrast, Gupta *et al.* \[[@R33]\] reported that the percentage of responders to ramipril therapy was significantly higher in patients with the *II* genotype compared with those with the *ID* genotype. As there is an inconsistency of findings across studies, the effects of these polymorphisms on ramipril-related BP changes still remain unclear.

With regard to the other 2 AGT SNPs (*M235T*and*T174M*), to our knowledge, the present study is the first to evaluate their association with ramipril efficacy, reporting no correlations. It should be noted that the main limitation of this study is the relatively small sample size.

CONCLUSION
==========

In the present study, we found that only the frequency of *AGTM235T (rs699)* variant is significantly (p=0.045) different between hypertensives and controls. No gender differences in the frequency of *AGTT174M (rs4762),*

*AGTM235T (rs1799752)* and *ACEI/D (rs1799752)* gene polymorphisms were observed in both study groups. Furthermore, these 3 SNPs did not influence the BP-lowering efficacy of ramipril. However, as this is a small study, future research on larger populations is needed to establish these associations.
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![*AGTM235T* gene polymorphism. 1, 7, 9: TT genotype; 2, 4, 6: MT genotype; 3, 5, 6: MM genotype\
**Abbreviations**: AGT: Angiotensinogen.](TOCMJ-9-118_F1){#F1}

![*AGTT174M* gene polymorphism. 1-5, 8, 9: TT genotype; 6, 7: TM genotype.\
MM genotype was not detected in the study groups\
**Abbreviations**: ACE: Angiotensin-1-converting enzyme.](TOCMJ-9-118_F2){#F2}

###### 

Demographic data, clinical characteristics and lipid profile of the study groups.

                                       Group                                
  ---------------------------- ------- ------- -------------------- ------ --------------------
  Gender                       Men     44      53.0%                48     57.8%
                               Women   39      47.0%                35     42.2%
  CAD                          Yes     0       0.0%                 24     28.9%
                               No      83      100.0%               59     71.1%
  Stroke                       Yes     0       0.0%                 4      4.8%
                               No      83      100.0%               79     95.2%
  Smoking                      Yes     29      34.9%                10     12.0%
                               No      48      57.8%                41     49.3%
                               Ex      6       7.2%                 32     38.6%
  Diabetes                     Yes     0       0.0%                 23     27.7%
                               No      83      100.0%               60     72.3%
  Continuous variables                 Mean    Standard Deviation   Mean   Standard Deviation
  Age (yrs)                            56      20                   67     13
  BMI (kg/m2)                          24.5    3.1                  27.7   3.8
  TC (mg/dl)                           170     31                   231    60
  TG (mg/dl)                           82      26                   164    147
  HDL-C (mg/dl)                        48      13                   49     15
  LDL-C (mg/dl)                        107     28                   146    50
  Baseline DBP (mmHg)                  73      8                    88     11
  Baseline SBP (mmHg)                  123     12                   159    18
  DBP (mmHg) after treatment                                        76     9
  SBP (mmHg) after treatment                                        130    15

**Abbreviations:** CAD: coronary artery disease; BMI: body mass index; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol, SBP: systolic blood pressure, DBP: diastolic blood pressure

###### 

Frequency of the 3 Simple Nucleotide Polymorphisms (SNPs) in study groups.

                                       Group            
  ----------------- ---- ----- ------- ------- ------- -------
  AGTM235T          MM   30    36.1%   23      27.7%   0.042
                    MT   47    56.6%   43      51.8%    
                    TT   6     7.2%    17      20.5%    
  AGTT174M          TT   70    84.3%   65      78.3%   0.319
                    TM   13    15.7%   18      21.7%    
                    MM   0     0.0%    0       0.0%     
  ACEI/D            II   14    17.1%   11      13.3%   0.712
                    ID   38    46.3%   43      51.8%    
                    D    30    36.6%   29      34.9%    
  AGTM235 allele    M    107   64.5%   89      53.6%   0.045
                    T    59    35.5%   77      46.4%    
  AGTT174M allele   T    153   92.2%   148     89.2%   0.346
                    M    13    7.8%    18      10.8%    
  ACEI/D allele     I    66    40.2%   65      39.2%   0.840
                    D    98    59.8%   101     60.8%    

**Abbreviations**: AGT: Angiotensinogen; ACE: Angiotensin-1-converting enzyme.

###### 

Frequency of AGTM235T, AGTT174M and ACE I/D genotype polymorphisms and level of blood pressure \[grade 1 HYP (hypertension), High normal, Normal, and Optimal) defined by the European Society of Cardiology in Hypertensive group \[17\].

                   Blood Pressure                                     
  ---------- ---- ----------------- ------------ ------- ------------ -------
  AGTM235T   MM   7                 33.3%        13      25.0%        0.770
             MT   10                47.6%        28      53.8%         
             TT   4                 19.0%        11      21.2%         
  AGTT174M   TT   16                76.2%        41      78.8%        0.999
             TM   5                 23.8%        11      21.2%         
             MM   0                 0.0%         0       0.0%          
  ACEI/D     II   2                 9.5%         7       13.5%        0.887
             ID   11                52.4%        27      51.9%         
             D    8                 38.1%        18      34.6%         
                   Blood pressure                                     
                  High Normal        Normal                           
                  Count             Column N %   Count   Column N %   p
  AGTM235T   MM   11                26.8%        9       28.1%        0.948
             MT   22                53.7%        16      50.0%         
             TT   8                 19.5%        7       21.9%         
  AGTT174M   TT   31                75.6%        26      81.3%        0.563
             TM   10                24.4%        6       18.8%         
             MM   0                 0.0%         0       0.0%          
  ACEI/D     II   5                 12.2%        4       12.5%        0.223
             ID   18                43.9%        20      62.5%         
             D    18                43.9%        8       25.0%         
                   Blood pressure                                     
                   Normal            Optimal                          
                  Count             Column N %   Count   Column N %   p
  AGTM235T   MM   17                28.8%        3       21.4%        0.736
             MT   31                52.5%        7       50.0%         
             TT   11                18.6%        4       28.6%         
  AGTT174M   TT   47                79.7%        10      71.4%        0.721
             TM   12                20.3%        4       28.6%         
             MM   0                 0.0%         0       0.0%          
  ACEI/D     II   8                 13.6%        1       7.1%         0.637
             ID   29                49.2%        9       64.3%         
             D    22                37.3%        4       28.6%         

Grade 1 hypertension (140-159 and/or 90-99 mmHg), High normal (130-139 and/or 85-89 mmHg), Normal (120-129 and/or 80-84 mmHg) and Optimal (\<120/\<80 mmHg).

**Abbreviations**: AGT: Angiotensinogen; ACE: Angiotensin-1-converting enzyme.

###### 

Allele Frequency of AGTM235T, AGTT174M and ACE I/D gene polymorphisms level of blood pressure \[grade 1 HYP (hypertension), High normal, Normal, and Optimal) defined by the European Society of Cardiology in Hypertensive group \[17\].

                 Blood Pressure                                               
  ---------- --- -------------------------- ------------ ------- ------------ -------
  AGTM235T   M   24                         57.1%        54      51.9%        0.567
             T   18                         42.9%        50      48.1%         
  AGTT174M   T   37                         88.1%        93      89.4%        0.816
             M   5                          11.9%        11      10.6%         
  ACEI/D     I   15                         35.7%        41      39.4%        0.677
             D   27                         64.3%        63      60.6%         
  AGTM235T   M   44                         53.7%        34      53.1%        0.949
             T   38                         46.3%        30      46.9%         
  AGTT174M   T   72                         87.8%        58      90.6%        0.588
             M   10                         12.2%        6       9.4%          
  ACEI/D     I   28                         34.1%        28      43.8%        0.236
             D   54                         65.9%        36      56.3%         
                 Blood pressure (optimal)                                     
                 Normal                     Optimal                           
                 Count                      Column N %   Count   Column N %    
  AGTM235T   M   65                         55.1%        13      46.4%        0.409
             T   53                         44.9%        15      53.6%         
  AGTT174M   T   106                        89.8%        24      85.7%        0.738
             M   12                         10.2%        4       14.3%         
  ACEI/D     I   45                         38.1%        11      39.3%        0.910
             D   73                         61.9%        17      60.7%         

Grade 1 hypertension (140-159 and/or 90-99 mmHg), High normal (130-139 and/or 85-89 mmHg), Normal (120-129 and/or 80-84 mmHg) and Optimal (\<120/\<80 mmHg).

Abbreviations: AGT: Angiotensinogen; ACE: Angiotensin-1-converting enzyme

###### 

Genotype and alleles in association with blood pressure differences changes.

                         Systolic Blood Pressure                        Diastolic Blood Pressure                                 
  ----------------- ---- ------------------------- -------------------- --------------------------- ------- -------------------- -------
  AGTM235T          MM   -22.9                     26.1                 0.282                       -8.4    12.7                 0.521
                    MT   -32.6                     20.6                                             -12.2   11.7                  
                    TT   -31.9                     20.4                                             -11.3   11.0                  
  AGTT174M          TT   -29.8                     22.9                 0.977                       -10.9   12.0                 0.909
                    TM   -30.0                     20.3                                             -11.3   11.4                  
                    MM    0.0                       0.0                                              0.0     0.0                  
  ACEI/D            II   -20.0                     31.8                 0.282                       -6.1    14.5                 0.409
                    ID   -32.9                     22.0                                             -11.9   11.1                  
                    D    -28.7                     17.8                                             -11.4   11.9                  
                         Systolic blood pressure                         Diastolic blood pressure                                
                         Mean                      Standard Deviation   p                           Mean    Standard Deviation   p
  AGTM235T allele   M    -27.7                     23.7                 0.216                       -10.3   12.2                 0.449
                    T    -32.3                     20.2                                             -11.8   11.2                  
  AGTT174M allele   T    -29.8                     22.4                 0.979                       -11.0   11.8                 0.915
                    M    -30.0                     20.3                                             -11.3   11.4                  
  ACEI/D allele     I    -28.8                     25.6                 0.637                       -10.1   12.3                 0.442
                    D    -30.6                     19.7                                             -11.6   11.4                  

Abbreviations: AGT: Angiotensinogen; ACE: Angiotensin-1-converting enzyme.
